The China Continuous Glucose Monitoring Market was valued at USD 523.4 million in 2024 and is estimated to grow at a CAGR of 17.4% to reach USD 2.55 billion by 2034.
This upward trend is largely supported by a combination of factors, including the rising number of diabetes cases nationwide, a rapidly aging population, advancements in CGM technologies, and growing awareness through government-led health campaigns. CGM devices, which track glucose levels in real time throughout the day and night using subcutaneous sensors, are becoming increasingly vital in the diabetes care ecosystem. Their growing importance in proactive disease management, especially in elderly and chronic care patients, has led to widespread adoption across both clinical and home care settings. Major manufacturers such as Medtronic, Abbott Laboratories, Dexcom, and Sinocare are playing pivotal roles in transforming this space with user-friendly solutions. As the Chinese healthcare sector accelerates its focus on chronic disease management, CGMs are gaining prominence for their ability to provide continuous, real-time insights, allowing for better glycemic control and reduced complications associated with diabetes.
The sensor component segment was valued at USD 265.5 million in 2024 and is anticipated to reach USD 1.3 billion by 2034 at a CAGR of 17.5%. This growth stems from a sharp shift toward at-home care and personalized health monitoring. Within CGM systems, sensors continuously assess glucose levels in the interstitial fluid, while transmitters collect these readings and relay the data to connected devices such as smartphones or dedicated receivers. These transmitters form the bridge between the sensor and the user's monitoring interface, allowing for real-time updates without the need for traditional fingerstick testing. Such connectivity supports remote monitoring by healthcare professionals and enhances compliance among users.
In 2024, the home care settings generated USD 424 million and held an 81% share. This segment continues to witness strong momentum, primarily driven by the high incidence of diabetes across the country. With an increasing focus on remote health monitoring, CGMs are emerging as a preferred solution for at-home diabetes care. These devices alert users in real time about significant glucose fluctuations, enabling timely intervention and reducing the need for frequent hospital visits. Enhanced usability, improved sensor life, and easy smartphone integration have broadened their appeal across all age groups.
Leading players operating in the China Continuous Glucose Monitoring Industry include Dexcom, Jiangsu Yuyue Medical Equipment & Supply, Abbott Laboratories, Senseonics, Medtrum Technologies, Med Trust, Medtronic, Zhejiang POCTech, and Sinocare. These companies continue to invest in R&D, device miniaturization, and AI-based glucose trend analysis to offer differentiated products for the growing Chinese market. Companies operating in China continuous glucose monitoring market are adopting a multi-tiered strategy to build market dominance. First, they are investing significantly in R&D to enhance sensor accuracy, extend sensor wear duration, and develop wireless capabilities for seamless data sharing. Many firms are also forming collaborations with local healthcare providers to strengthen distribution channels and increase patient accessibility. Additionally, several players are pursuing regulatory approvals to fast-track product launches.
This product will be delivered within 2-4 business days.
This upward trend is largely supported by a combination of factors, including the rising number of diabetes cases nationwide, a rapidly aging population, advancements in CGM technologies, and growing awareness through government-led health campaigns. CGM devices, which track glucose levels in real time throughout the day and night using subcutaneous sensors, are becoming increasingly vital in the diabetes care ecosystem. Their growing importance in proactive disease management, especially in elderly and chronic care patients, has led to widespread adoption across both clinical and home care settings. Major manufacturers such as Medtronic, Abbott Laboratories, Dexcom, and Sinocare are playing pivotal roles in transforming this space with user-friendly solutions. As the Chinese healthcare sector accelerates its focus on chronic disease management, CGMs are gaining prominence for their ability to provide continuous, real-time insights, allowing for better glycemic control and reduced complications associated with diabetes.
The sensor component segment was valued at USD 265.5 million in 2024 and is anticipated to reach USD 1.3 billion by 2034 at a CAGR of 17.5%. This growth stems from a sharp shift toward at-home care and personalized health monitoring. Within CGM systems, sensors continuously assess glucose levels in the interstitial fluid, while transmitters collect these readings and relay the data to connected devices such as smartphones or dedicated receivers. These transmitters form the bridge between the sensor and the user's monitoring interface, allowing for real-time updates without the need for traditional fingerstick testing. Such connectivity supports remote monitoring by healthcare professionals and enhances compliance among users.
In 2024, the home care settings generated USD 424 million and held an 81% share. This segment continues to witness strong momentum, primarily driven by the high incidence of diabetes across the country. With an increasing focus on remote health monitoring, CGMs are emerging as a preferred solution for at-home diabetes care. These devices alert users in real time about significant glucose fluctuations, enabling timely intervention and reducing the need for frequent hospital visits. Enhanced usability, improved sensor life, and easy smartphone integration have broadened their appeal across all age groups.
Leading players operating in the China Continuous Glucose Monitoring Industry include Dexcom, Jiangsu Yuyue Medical Equipment & Supply, Abbott Laboratories, Senseonics, Medtrum Technologies, Med Trust, Medtronic, Zhejiang POCTech, and Sinocare. These companies continue to invest in R&D, device miniaturization, and AI-based glucose trend analysis to offer differentiated products for the growing Chinese market. Companies operating in China continuous glucose monitoring market are adopting a multi-tiered strategy to build market dominance. First, they are investing significantly in R&D to enhance sensor accuracy, extend sensor wear duration, and develop wireless capabilities for seamless data sharing. Many firms are also forming collaborations with local healthcare providers to strengthen distribution channels and increase patient accessibility. Additionally, several players are pursuing regulatory approvals to fast-track product launches.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2024
Chapter 5 Market Estimates and Forecast, by Component, 2021-2034 ($ Mn)
Chapter 6 Market Estimates and Forecast, by End Use, 2021-2034 ($ Mn)
Chapter 7 Company Profiles
Companies Mentioned
The key companies profiled in this China Continuous Glucose Monitoring market report include:- Abbott Laboratories
- Dexcom
- Jiangsu Yuyue Medical Equipment & Supply
- Med Trust
- Medtronic
- Medtrum Technologies
- Senseonics
- Sinocare
- Zhejiang POCTech
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 65 |
| Published | September 2025 |
| Forecast Period | 2024 - 2034 |
| Estimated Market Value ( USD | $ 523.4 Million |
| Forecasted Market Value ( USD | $ 2550 Million |
| Compound Annual Growth Rate | 17.4% |
| Regions Covered | China |
| No. of Companies Mentioned | 10 |
